✦ LIBER ✦

A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty: The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: Study design and rationale

✍ Scribed by Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Martín J. Garcia-Gonzalez; Juan Carlos Kaski; Russel J. Reiter; Alejandro Jimenez-Sosa

Book ID: 116350613
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 137 KB
Volume: 28
Category: Article
ISSN: 1551-7144
DOI: 10.1016/j.cct.2006.10.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of Pexelizumab in Acute Myoca

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

✍ Paul W. Armstrong; Peter X. Adams; Hussein R. Al-Khalidi; Christian Hamm; David 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 179 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)

✍ Ik-Kyung Jang; Neil J. Weissman; Michael H. Picard; Michael R. Zile; Veronica Pe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 264 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB